{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-002831","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.539580+00:00","generated_at":"2026-06-06T21:54:31.969274+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lipocine licenses TLANDO franchise to Verity Pharma for $11M upfront, up to $259M milestones plus royalties","bullets":["Exclusive US/Canada rights to TLANDO and TLANDO XR; Lipocine receives $11M license fee ($2.5M paid, $5M due Feb 1, 2024).","Eligible for up to $259M in development and sales milestones plus tiered royalties of 12–18% on US/Canada net sales.","Commercialization transitions to Verity Pharma effective Feb 1, 2024; Verity handles all regulatory and marketing obligations.","Lipocine retains all rights outside US/Canada and all non-TRT indications globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-002831","json":"https://secwatch.observer/filing/0001493152-24-002831.json","markdown":"https://secwatch.observer/filing/0001493152-24-002831.md","text":"https://secwatch.observer/filing/0001493152-24-002831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/0001493152-24-002831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:54:31.969274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d136ed62a48c994634dbb31cb735f119448940e9","claim":"Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).","evidence_excerpt":"On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315224002831/0001493152-24-002831-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Gordon Silver Limited and Verity Pharmaceuticals, Inc."},{"label":"Value","value":"$11 million license fee"},{"label":"Effective","value":"2024-01-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}